ProMIS Neurosciences Inc.

Listed Company

PMNCIK 0001374339NasdaqEmerging GrowthPharmaceutical PreparationsZ4CHFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-39.72M

Total Assets

$9.18M

Equity

$-1.26M

Shares Out

8.97M

Op. Cash Flow

$-28.10M

Business

ProMIS Neurosciences Inc. in-licenses and applies a proprietary computational platform to develop antibody therapies, therapeutic vaccines, and related biologics targeting misfolded proteins implicated in neurodegenerative and protein-misfolding diseases. Its main offerings comprise selective monoclonal antibodies, intrabodies and peptide‑based vaccine candidates directed at toxic conformers of proteins such as amyloid‑beta, alpha‑synuclein, TDP‑43, tau, RACK1 and DISC1. The company organizes activities around discovery, preclinical development, IND‑enabling studies and clinical programs for lead candidates. ProMIS pursues regulatory, clinical and commercialization activities primarily in the United States and Canada and plans to out‑license marketing to partners and distributors.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	33	11	8	16	5
General and administrative	7	6	6	7	4
Total operating expenses	40	17	14	23	8
Loss from operations	−40	−17	−14	−23	−8
Change in fair value of financial instruments	5,592	23	866,738	4	−1
Interest expense	—	−76,775	−201,390	—	—
Other income	442,569	626,184	384,903	115,525	12,909
Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE	—	−4	—	—	—
Total other income, net	448,161	20	1	5	−1
Net (loss) income	−40	3	−13	−18	−10
Net (loss) income per share, basic	−22.61	2.68	−1.07	−2.41	−1.69
Net (loss) income per share, diluted	−22.61	2.63	−1.07	−2.41	−1.69
Weighted-average outstanding Common Shares, basic	2	1	12	8	6
Weighted-average outstanding Common Shares, diluted	2	1	12	8	6

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	6	13	13	6	17
Short-term investments	33,753	33,051	32,358	31,009	33,248
Prepaid expenses and other current assets	3	6	988,641	996,682	737,316
Total current assets	9	19	14	7	18
Total assets	9	19	14	7	18
Accounts payable	3	2	8	3	408,981
Accrued liabilities	8	480,962	2	3	520,093
Total current liabilities	10	2	9	6	929,074
Share-based compensation liability	29,182	199,263	422,002	—	—
Warrant liability	—	5,592	94,185	2	2
Total liabilities	10	2	10	8	12
Commitments and contingencies	—	—	—	—	—
Common Shares, no par value, unlimited shares authorized, 2,152,397 and 1,307,520 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	—	—	—	—	—
Additional paid-in capital	130	108	98	79	68
Accumulated other comprehensive loss	−371,184	−371,184	−371,184	−195,369	−187,919
Accumulated deficit	−130	−91	−93	−80	−62
Total shareholders' (deficit) equity	−1	16	4	−1	6
Total liabilities and shareholders' (deficit) equity	9	19	14	7	18

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net (loss) income	−40	3	−13	−18	−10
Share-based compensation expense	857,628	825,808	271,542	487,630	515,629
Change in fair value of financial instruments	−5,592	−23	−866,738	−3	2
Prepaid expenses and other current assets	3	−5	−187,321	−318,747	−600,635
Accounts payable	805,952	−6	5	3	−31,654
Accrued liabilities	7	−1	−2	3	471,463
Net cash used in operating activities	−28	−27	−11	−17	−9
Purchase of short-term investments	−33,753	−33,051	−32,358	−31,009	−33,102
Maturity of short-term investment	33,051	32,358	31,009	31,009	33,069
Net cash used in investing activities	−702	−693	−1,349	−1,981	94,618
Proceeds from issuance of Common Shares pursuant to 2025 and 2024 ATM offering, respectively, net of issuance costs	708,468	190,274	—	5	16
Proceeds from exercise of pre-funded warrants	3,050	28,038	3,600	—	—
Net cash provided by financing activities	21	28	18	6	26
Net (decrease) increase in cash	−7	693,021	7	−11	16
Reclassification of July 2024 PIPE warrants from liability to equity	—	9	—	—	—
Decrease in share-based compensation liability on CAD denominated share options increasing additional paid-in-capital	−170,081	222,739	681,308	—	—
Cash paid for interest	—	76,775	201,390	87,069	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro